跳至主要内容
临床试验/NCT05180838
NCT05180838已完成不适用

Remote Data Capture of Elevated Temperature Data for Early Detection of Febrile Neutropenia in Patients With Hematologic Malignancies

University of Colorado, Denver2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年10月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
2
主要终点
Reliability of BioSticker compared to self-check

研究概览

简要总结

BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of ~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others.

详细描述

The BioIntelliSense BioSticker potentially offers a solution to these challenges through early and reliable detection of elevated temperature and perhaps other relevant physiologic changes. The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring (see https://biointellisense.com as well as attached documents on BioSticker instructions for a full description and use instructions). The BioSticker detects the following:

  • Respiratory rate, heart rate at rest and skin temperature
  • Body position, activity levels, sleep status
  • High-resolution gait analysis and fall detection
  • Symptomatic events

BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of ~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 18-80 years (inclusive)
  • Provision to sign and date the consent form.
  • Diagnosed with a hematologic malignancy and undergoing cytotoxic chemotherapy, stem cell transplants or CAR T-cell treatments at the Blood Disorders and Cell Therapies Center at UCHealth (BDCTC)
  • Will have longitudinal care provided by the BDCTC for >1 additional month
  • Receive chemotherapy or other therapies known to cause reductions in WBC <1000 on a routine basis
  • Scheduled to be discharged home and self-monitor for FN and other complications
  • Patient is willing to tell TSA or any security representative that you are wearing a "medical device"
  • Patient has agreed to not submerge the device underwater including while swimming or bathing
  • Patient is willing to complete a self-check temperature log comply and be available for the duration of the study
  • Patient has access to a thermometer

排除标准

  • Patient that wears a defibrillator, pacemaker, or other implantable device
  • Patient has broken skin including wounds, sores, or abrasions in the area that the BioSticker would be applied
  • Patient has had a severe reaction to silicone adhesives
  • Patient has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.

结局指标

主要结局

Reliability of BioSticker compared to self-check

时间窗: 28 days

Patients will self-temperature check every 6 hours or at least two times per day, and will log these temperatures in a paper record with date, time and temperature noted.

次要结局

  • BioSticker Impact on Delays in Chemotherapy(28 days)
  • BioSticker Impact on Length of Hospitalization(28 days)
  • BioSticker Impact on Patient reported temperature(28 days)
  • BioSticker Impact on ICU transfers(28 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验